Natalizumab in the treatment of pediatric multiple sclerosis. Talab R, Talabova M, Klzo L. Case Reports 2012; 33(6): 579-589 PubMed PMID: 23160229 Keywords: Adult, Antibodies, Monoclonal, Humanized:therapeutic use, Brain:pathology, Drug Resistance, Female, Humans, Magnetic Resonance Imaging, Male, Multiple Sclerosis:drug therapy, Natalizumab, Secondary Prevention, Treatment Outcome, Young Adult,. Citation : Pediatric cerebrospinal multiple sclerosis (MS) constitutes about 2-5% of all MS cases. The International Pediatric MS Study Group (IPMS..... Read abstract Full text PDF